KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Inventory (2017 - 2025)

Novartis Ag's Inventory history spans 9 years, with the latest figure at $6.3 billion for Q4 2025.

  • For Q4 2025, Inventory rose 9.54% year-over-year to $6.3 billion; the TTM value through Dec 2025 reached $6.3 billion, up 9.54%, while the annual FY2025 figure was $6.3 billion, 9.54% up from the prior year.
  • Inventory for Q4 2025 was $6.3 billion at Novartis Ag, up from $5.7 billion in the prior quarter.
  • Across five years, Inventory topped out at $7.2 billion in Q4 2022 and bottomed at $5.7 billion in Q4 2024.
  • The 5-year median for Inventory is $6.3 billion (2025), against an average of $6.3 billion.
  • The largest annual shift saw Inventory decreased 17.59% in 2023 before it grew 9.54% in 2025.
  • A 5-year view of Inventory shows it stood at $6.7 billion in 2021, then grew by 7.64% to $7.2 billion in 2022, then dropped by 17.59% to $5.9 billion in 2023, then decreased by 3.21% to $5.7 billion in 2024, then rose by 9.54% to $6.3 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Inventory are $6.3 billion (Q4 2025), $5.7 billion (Q4 2024), and $5.9 billion (Q4 2023).